Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

7 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Early nonresponse determined by the clinical global impressions scale predicts poorer outcomes in youth with schizophrenia spectrum disorders naturalistically treated with second-generation antipsychotics.
Stentebjerg-Olesen M, Jeppesen P, Pagsberg AK, Fink-Jensen A, Kapoor S, Chekuri R, Carbon M, Al-Jadiri A, Kishimoto T, Kane JM, Correll CU. Stentebjerg-Olesen M, et al. J Child Adolesc Psychopharmacol. 2013 Dec;23(10):665-75. doi: 10.1089/cap.2013.0007. Epub 2013 Nov 22. J Child Adolesc Psychopharmacol. 2013. PMID: 24266529 Free PMC article.
Early response or nonresponse at week 2 and week 3 predict ultimate response or nonresponse in adolescents with schizophrenia treated with olanzapine: results from a 6-week randomized, placebo-controlled trial.
Stentebjerg-Olesen M, Ganocy SJ, Findling RL, Chang K, DelBello MP, Kane JM, Tohen M, Jeppesen P, Correll CU. Stentebjerg-Olesen M, et al. Eur Child Adolesc Psychiatry. 2015 Dec;24(12):1485-96. doi: 10.1007/s00787-015-0725-1. Epub 2015 Jun 2. Eur Child Adolesc Psychiatry. 2015. PMID: 26032132 Clinical Trial.
Change and dispersion of QT interval during treatment with quetiapine extended release versus aripiprazole in children and adolescents with first-episode psychosis: results from the TEA trial.
Jensen KG, Gärtner S, Correll CU, Rudå D, Klauber DG, Stentebjerg-Olesen M, Fagerlund B, Jepsen JR, Fink-Jensen A, Juul K, Pagsberg AK. Jensen KG, et al. Among authors: stentebjerg olesen m. Psychopharmacology (Berl). 2018 Mar;235(3):681-693. doi: 10.1007/s00213-017-4784-5. Epub 2017 Nov 29. Psychopharmacology (Berl). 2018. PMID: 29185022 Clinical Trial.
Quetiapine versus aripiprazole in children and adolescents with psychosis--protocol for the randomised, blinded clinical Tolerability and Efficacy of Antipsychotics (TEA) trial.
Pagsberg AK, Jeppesen P, Klauber DG, Jensen KG, Rudå D, Stentebjerg-Olesen M, Jantzen P, Rasmussen S, Saldeen EA, Lauritsen MB, Bilenberg N, Stenstrøm AD, Pedersen J, Nyvang L, Madsen S, Lauritsen MB, Vernal DL, Thomsen PH, Paludan J, Werge TM, Winge K, Juul K, Gluud C, Skoog M, Wetterslev J, Jepsen JR, Correll CU, Fink-Jensen A, Fagerlund B. Pagsberg AK, et al. Among authors: stentebjerg olesen m. BMC Psychiatry. 2014 Jul 11;14:199. doi: 10.1186/1471-244X-14-199. BMC Psychiatry. 2014. PMID: 25015535 Free PMC article. Clinical Trial.
Quetiapine extended release versus aripiprazole in children and adolescents with first-episode psychosis: the multicentre, double-blind, randomised tolerability and efficacy of antipsychotics (TEA) trial.
Pagsberg AK, Jeppesen P, Klauber DG, Jensen KG, Rudå D, Stentebjerg-Olesen M, Jantzen P, Rasmussen S, Saldeen EA, Lauritsen MG, Bilenberg N, Stenstrøm AD, Nyvang L, Madsen S, Werge TM, Lange T, Gluud C, Skoog M, Winkel P, Jepsen JRM, Fagerlund B, Correll CU, Fink-Jensen A. Pagsberg AK, et al. Among authors: stentebjerg olesen m. Lancet Psychiatry. 2017 Aug;4(8):605-618. doi: 10.1016/S2215-0366(17)30166-9. Epub 2017 Jun 7. Lancet Psychiatry. 2017. PMID: 28599949 Clinical Trial.